---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006898"
form_type: "8-K"
ticker: "OPK"
cik: "0000944809"
company_name: "OPKO HEALTH, INC."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-25T00:36:20.118445+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OPKO Health to sell oncology testing assets to Labcorp for up to $225M

## Summary
- Purchase price: $192.5M at closing plus up to $32.5M in earnout based on performance.
- Divested assets generate ~$85-100M in annual revenue; deal expected to close H2 2025.
- BioReference retains core NY/NJ clinical testing and 4Kscore franchise (~$300M 2024 revenue).
- Labcorp expects acquisition to be accretive to earnings in year one.
- Transaction includes customary closing conditions and state regulatory approvals.

## SEC filing metadata
- accession: 0001437749-25-006898
- form_type: 8-K
- ticker: OPK
- cik: 0000944809
- company_name: OPKO HEALTH, INC.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/944809/000143774925006898/0001437749-25-006898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/944809/000143774925006898/opk20250305c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006898
- JSON: https://secwatch.observer/filing/0001437749-25-006898.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.